GlassScriptPhysician profile
Udele Taylor-Randall
NPI 1184653750
$2,923.28
in general payments reported to CMS, 2019-2025
15 companies · $279 in 2025
The $279 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $581 · 2020: $163 · 2021: $589 · 2022: $723 · 2023: $209 · 2024: $379 · 2025: $279.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $630 · Education: $237.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $630.37 |
| Education | $236.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $925.15 | 2019-2023 | Orilissa |
| Astellas Pharma US INC | $567.67 | 2023-2025 | Veozah, Myrbetriq |
| Myovant Sciences INC. | $356.66 | 2021-2022 | |
| Lupin INC. | $336.19 | 2019-2021 | |
| Scynexis, INC. | $238.61 | 2021-2022 | |
| Pfizer INC. | $142.46 | 2022-2024 | |
| Sumitomo Pharma America, INC. | $73.80 | 2023-2025 | Myfembree |
| Mayne Pharma Commercial LLC | $54.92 | 2022-2023 | |
| Vertex Pharmaceuticals Incorporated | $48.41 | 2024-2025 | |
| Coopersurgical, INC. | $44.45 | 2021-2022 | |
| Evofem Biosciences, INC. | $35.69 | 2021 | |
| Agile Therapeutics, INC. | $34.44 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $28.22 | 2022 | |
| Biocryst US Sales Co., LLC | $21.45 | 2022 | |
| Shield Therapeutics INC | $15.16 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Udele Taylor-Randall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.